Resources for Patients and Caregivers

At KaloBios, we aim to develop treatments that improve the lives of patients with cancers. But patients and their families dealing with a cancer diagnosis need more than effective treatments. We understand their need for information, support, advocacy and other help that comes along with a diagnosis for cancer.

Current KaloBios-Sponsored Clinical Trials

Patient Resources and Information

Myelodysplastic Syndromes (MDS) -- MDS is a classification of cancers that affect bone-marrow stem cells, which results in fewer than normal mature blood cells in circulation. In most cases, MDS are progressive diseases that advances over time to bone marrow failure. In advanced stages of MDS, the disease may progress to Acute Myelogenous Leukemia (AML), which affects about one-third of patients with MDS. According to the Leukemia & Lymphoma Society, the overall incidence of MDS is approximately 4.9 of every 100,000 people. MDS may arise de novo or secondarily, after treatment for other cancers. It is also associated with benzene exposure, often as a result of smoking tobacco or exposure to secondary tobacco smoke.

Myelofibrosis (MF) --- MF is a chronic blood cancer in which excessive scar tissues forms in the bone marrow and impairs its ability to produce normal blood cells. Experts believe it results from abnormal blood stem cells in the bone marrow that produce more mature cells that grow quickly and take over the bone marrow, causing both scarring (fibrosis) and chronic inflammation. Some people with MF can live for many years with only mild symptoms; in others the disease progresses more quickly. For a small number of patients, MF can progress to AML and rapidly become fatal. In the U.S., studies estimate MF prevalence range from 3.6-5.7 per 100,000 patients.

Chronic Myelomonocytic Leukemia (CMML) -- CMML is a form of blood cancer that starts in the bone marrow and invades the bloodstream. This results in high numbers of monocytes in the blood stream, causing total white blood cell counts to become very high as well. About 15% - 30% of CMML patients progress to AML. CMML is a rare cancer, occurring in 4 of every million people in the United States each year (about 1,100 cases annually) according to the American Cancer Society.

Further Clinical Trials Information

About KaloBios

KaloBios Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today's marketed antibody products.

Learn More
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue